Us food and drug administration declines emergency use authorization for zyesami® (aviptadil) for patients with critical covid-19 with respiratory failure

Radnor, pa., nov. 4, 2021 /prnewswire/ -- nrx pharmaceuticals (nasdaq: nrxp), a clinical-stage biopharmaceutical company (nrx), today announced that the us food and drug administration (fda) has declined to issue an emergency use authorization (eua) for zyesami® (aviptadil).

NRXP Ratings Summary

NRXP Quant Ranking